Cingulate Inc. 8-K

What Happened

• Cingulate Inc. (CING) filed an 8-K on March 18, 2026 to announce its financial results for the year ended December 31, 2025 and to provide a business update. The company furnished a press release dated March 18, 2026 as Exhibit 99.1.
• Separately, on March 17, 2026 the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering Cingulate’s lead asset, CTx-1301 (dexmethylphenidate), for the treatment of ADHD. Once the patent is granted, protection would extend through May 2042.

Key Details

• 8-K filed: March 18, 2026 (Item 2.02 — Results of Operations and Financial Condition; Exhibit 99.1 press release).
• Reporting period: year ended December 31, 2025 (financial results announced in the press release).
• Patent action: USPTO Notice of Allowance issued March 17, 2026 for CTx-1301 (dexmethylphenidate).
• Expected patent term (when granted): protection extending through May 2042.

Why It Matters

• The 8-K signals the company has released its full-year 2025 financial results and a business update; investors should review the March 18, 2026 press release (Exhibit 99.1) for revenue, profit/loss, cash position, and guidance details not included in the 8-K text.
• The USPTO Notice of Allowance for CTx-1301 is a material development for Cingulate’s lead asset: granted patent protection (through May 2042) could strengthen exclusivity and long-term value for that drug candidate, subject to final grant and regulatory outcomes.